Mucin 1 (MUC1)-derived peptide–Major Histocompatibility Complex (MHC) complex on plasmacytoid dendritic cells (MUC1-pMHC on pDCs)

The Mucin 1 (MUC1)-derived peptide–Major Histocompatibility Complex (MHC) complex on plasmacytoid dendritic cells (pDCs) is a specialized immunological assembly that serves as a critical intermediate in the induction of anti-tumor immunity. MUC1 is a transmembrane glycoprotein that is frequently overexpressed and aberrantly glycosylated in various epithelial cancers, including breast, lung, colorectal, and pancreatic cancers, making it a prominent tumor-associated antigen. Plasmacytoid dendritic cells are a unique subset of antigen-presenting cells known for their ability to produce high levels of Type I interferons and play a crucial role in priming T-cell responses. In the context of immunotherapies like the Versamune-based vaccine PDS0103, the drug delivers MUC1 peptides and activates pDCs to ensure the efficient presentation of these peptides on MHC molecules. This specific complex on the pDC surface provides the necessary signals to activate and expand MUC1-specific cytotoxic T lymphocytes (CTLs), which then circulate to recognize and eliminate MUC1-expressing tumor cells. Consequently, this complex is a key target for therapeutic strategies aimed at overcoming immune tolerance and generating a potent, targeted, and durable anti-cancer immune response.

Other names

MUC1-pMHC complex on pDCsMUC1-HLA complex on plasmacytoid dendritic cellsMUC1 peptide-MHC class I complexMUC1-derived peptide-MHC class II complexVersamune-induced MUC1-pMHC complex

PDS0103 delivers MUC1-derived agonist peptides to plasmacytoid dendritic cells (pDCs) and activates them via the Versamune platform (a cationic lipid adjuvant); the pDCs then process and present the MUC1-derived peptide–MHC complex on their surface to prime and expand MUC1-specific CD8+ and CD4+ T cells.